Table 5 Univariate and multivariate analyses of survival for the ineligible group (n = 84).

Sex, female

0.67

0.43–1.06

0.09

Age, ≥ 68 years

1.24

0.78–1.97

0.37

Performance status, 2–3

3.26

2.02–5.24

< 0.01

2.90

1.77–4.74

< 0.01

Tumor location, middle/lower

0.71

0.44–1.14

0.15

Macroscopic type, type 4

1.03

0.65–1.65

0.90

Number of distant metastatic sites, ≥ 2

1.85

1.08–3.17

0.03

1.27

0.73–2.21

0.40

Liver metastasis, presence

0.88

0.49–1.58

0.66

Distant lymph node metastasis, presence

1.49

0.89–2.49

0.13

Peritoneal dissemination, presence

1.35

0.80–2.28

0.26

Bone metastasis, presence

1.45

0.45–4.64

0.53

Histological type, undifferentiated

1.18

0.67–2.08

0.57

First-line regimen of chemotherapy, S-1 alone

3.71

0.85–16.28

0.08

First-line regimen of chemotherapy, platinum-based

1.17

0.74–1.87

0.50

Disease control, PD

4.76

2.78–8.17

< 0.01

4.11

2.35–7.19

< 0.01

Conversion surgery, presence

0.14

0.06–0.33

< 0.01

0.20

0.08–0.49

< 0.01